(-)-(4aR,8S,8aS,10aS)-(4aα,8α,8aα,10aβ)-8-acetoxy-3,4,4a,6,7,8,8a,9,10,10a-decahydro-1,1,4a,8a-tetramethylphenanthren-2(1H)-one | 670246-66-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (-)-(4aR,8S,8aS,10aS)-(4aα,8α,8aα,10aβ)-8-acetoxy-3,4,4a,6,7,8,8a,9,10,10a-decahydro-1,1,4a,8a-tetramethylphenanthren-2(1H)-one
• 英文别名: (-)-(1S,4bR,8aS,10aS)-4b,8,8,10a-tetramethyl-7-oxo-1,2,3,4b,5,6,7,8,8a,9,10,10a-dodecahydrophenanthren-1-yl ethanoate；[(1S,4bR,8aS,10aS)-4b,8,8,10a-tetramethyl-7-oxo-1,2,3,5,6,8a,9,10-octahydrophenanthren-1-yl] acetate
• CAS: 670246-66-9
• 化学式: C₂₀H₃₀O₃
• 分子量: 318.456
• InChiKey: OQWPPIAJADETHX-FPWFTKFVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (-)-(4aR,8S,8aS,10aS)-(4aα,8α,8aα,10aβ)-8-acetoxy-3,4,4a,6,7,8,8a,9,10,10a-decahydro-1,1,4a,8a-tetramethylphenanthren-2(1H)-one 在 chromium(VI) oxide 、 叔丁基过氧化氢 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二氯甲烷 为溶剂， 反应 10.5h， 生成 (+)-(4aR,8aR,10aS)-(4aα,8aα,10aβ)-4,4a,8a,9,10,10a-hexahydro-1,1,4a,8a-tetramethylphenanthrene-2,6(1H,3H)-dione
  参考文献：
  名称：

  在环A和C中高效合成具有烯酮功能的（-）-和（+）-三环化合物。一类新型的口服活性抗炎和癌症化学预防剂。

  摘要：

  根据合成的三萜类化合物2-氰基-3,12-二氧代油酸酯-1,9（11）的结构设计了在环A和环C具有烯酮官能团的新型三环化合物[三环-双-烯酮（TBE）化合物]。 ）-二烯-28-油酸（CDDO）（1），它是预防和/或治疗癌症和炎症性疾病的有前途的候选药物，其发病机理可能涉及一氧化氮（NO）和/或前列腺素的过量生产。一系列外消旋形式的TBE化合物显示出对小鼠巨噬细胞中干扰素-γ（IFN-γ）诱导的NO产生的高抑制活性。这些化合物之一，（+/-）-（4a [小β，8a [小β，10a [小α]）-1,2,4a，6,8a，9,10,10a-八氢-1 ，1,4a，8a-tetramethyl-2,6-dioxophenanthren e-3,7-dicarbonitrile（（+/-）-3），在一项初步研究中，使用硫代乙醇酸酯和IFN-γ诱导的小鼠腹膜炎症，口服活性为15 mg kg（-1）（单次

  DOI：

  10.1039/b307491a
• 作为产物：
  描述：

  (4aSR,8RS,8aRS)-8-hydroxy-1,4a,8a-trimethyl-4,4a,6,7,8,8a,9,10-octahydrophenanthren-2(3H)-one 在 吡啶 、 lithium 作用下， 以 四氢呋喃 、 氨 为溶剂， 生成 (-)-(4aR,8S,8aS,10aS)-(4aα,8α,8aα,10aβ)-8-acetoxy-3,4,4a,6,7,8,8a,9,10,10a-decahydro-1,1,4a,8a-tetramethylphenanthren-2(1H)-one
  参考文献：
  名称：

  Tricyclic Compounds Containing Nonenolizable Cyano Enones. A Novel Class of Highly Potent Anti-Inflammatory and Cytoprotective Agents

  摘要：

  Forty-four novel tricycles containing nonenolizable cyano enones (TCEs) were designed and synthesized on the basis of a semisynthetic pentacyclic triterpenoid, bardoxolone methyl, which is currently being developed in phase II clinical trials for the treatment of severe chronic kidney disease in diabetic patients. Most of the TCEs having two different kinds of nonenolizable cyano enones in rings A and C are highly potent suppressors of induction of inducible nitric oxide synthase stimulated with interferon-gamma and are highly potent inducers of the cytoprotective enzymes heme oxygenase-1 and NAD(P)H:quinone oxidoreductase-1. Among these compounds, (+/-)-(4bS,8aR,10aS)-10a-ethynyl-4b,8,8-trimethyl-3,7-dioxo-3,4b,7,8,8a,9,10,10a-octahydrophenanthrene-2,6-dicarbonitrile ((+/-)-31) is the most potent in these bioassays in our pool of drug candidates including semisynthetic triterpenoids and synthetic tricycles. These facts strongly suggest that an essential factor for potency is not a triterpenoid skeleton but the cyano enone functionality. Notably, TCE 31 reduces hepatic tumorigenesis induced with aflatoxin in rats. Further preclinical studies and detailed mechanism studies on 31 are in progress.

  DOI：

  10.1021/jm101445p

文献信息

• Design and Synthesis of Tricyclic Compounds with Enone Functionalities in Rings A and C:  A Novel Class of Highly Active Inhibitors of Nitric Oxide Production in Mouse Macrophages
  作者：Frank G. Favaloro,、Tadashi Honda、Yukiko Honda、Gordon W. Gribble、Nanjoo Suh、Renee Risingsong、Michael B. Sporn

  DOI：10.1021/jm025565f

  日期：2002.10.1

  Novel tricyclic compounds with enone functionalities in rings A and C, which were designed on the basis of the structure of a synthetic triterpenoid, 2-cyano-3,12-dioxo-oleana-1,9(11)-dien-28-oic acid, have been synthesized. Among them, 10 shows high inhibitory activity (IC50 = 1 nM level) against production of nitric oxide induced by interferon-gamma in mouse macrophages and is orally active at 15 mg/kg (once) in a preliminary in vivo study using mouse peritoneal inflammation induced by thioglycollate and interferon-gamma.